This problem has a solution, and Pfizer is implementing it.

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

Bourla’s confidence belied the reality facing Pfizer. Fewer people have been getting Covid-19 shots, denting revenues. In an ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Pfizer's non-COVID-19 portfolio demonstrates resilience, with Padcev, Vyndamax, and new launches driving operational growth despite patent cliffs. Learn more about PFE stock here.

Pfizer has lived up to its threat of taking legal action to prevent Metsera from slipping out of its grasp, but the obesity biotech also seems up for the fight. Last Thursday brought the bombshell ...

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion ...

Despite trading near decade-low valuations, Pfizer (NYSE:PFE) is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen ...

Pfizer's cardiovascular business highlights the intersection of drug pricing, marketing, patents, and competition in the ...

Pfizer (NYSE:PFE | PFE Price Prediction) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its ...

Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily ...